Catalytic antibodies for carbamate activation by a non-spontaneous reaction mechanism
AssigneeZeneca Limited
InventorsGeorge Michael Blackburn, Paul Wentworth
Life of this patent
Estimating the term…
Abstract
Catalytic antibodies capable of catalysing activation of a carbamate (--O--CO--NH--) containing prodrug suitable for Antibody Directed Abzyme Prodrug Therapy (ADAPT) by catalysing breakdown of the prodrug at the carbamate position by a non-spontaneous reaction mechanism. The non-spontaneous reaction preferably has a B.sub.Ac 2 mechanism and the prodrug is a preferably a nitrogen mustard aryl carbamate. The invention also includes relevant immunogens, screens for catalytic activity using short transition state analogues and ADAPT systems.
Claims23
A catalytic antibody capable of catalysing activation of a carbamate (--O--CO--NH--) containing prodrug suitable for Antibody Directed Abzyme Prodrug Therapy (ADAPT) by catalysing breakdown of the prodrug at the carbamate position by a non-spontaneous reaction mechanism.
Catalytic antibody BH3-B8-F9 as obtainable from hybridoma accession no. 96042611 as deposited at the European Collection of Animal Cell Cultures (ECACC).
Catalytic antibody DF8-D5 as obtainable from hybridoma accession no. 96042612 as deposited at the European Collection of Animal Cell Cultures (ECACC).
Dependencies are inferred from the claim text.